Serotonin syndrome complicating migraine pharmacotherapy

Cephalalgia

Volumn 16, Issue 5, 1996, Pages 323-327

  Mathew, N T ^a   Tietjen, G E ^b   Lucker, C ^a  

^a Houston Headache Clinic   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Migraine; Serotonin; Serotonin syndrome

Indexed keywords

AMITRIPTYLINE; DIHYDROERGOTAMINE; IMIPRAMINE; LITHIUM; NORTRIPTYLINE; PAROXETINE; SEROTONIN RECEPTOR; SERTRALINE; SUMATRIPTAN;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MIGRAINE; NEUROTOXICITY; SEROTONIN SYNDROME; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AUTONOMIC NERVOUS SYSTEM DISEASES; DIHYDROERGOTAMINE; DRUG SYNERGISM; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LITHIUM; MENTAL DISORDERS; MIGRAINE DISORDERS; MOVEMENT DISORDERS; SEROTONIN AGONISTS; SUMATRIPTAN; SYNDROME;

EID: 0029739769     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1996.1605323.x     Document Type: Article

References (37)

1. Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache: increase in the hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy 1961;19:55-8
2. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993;13:151-65
3. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology 1960;10:107-11
4. Humphrey PPA, Feniuk W, Perren MJ. Anti-migraine drugs in development: advances in serotonin receptor pharmacology. Headache 1990;30:12-6
5. Peroutka SJ. The pharmacology of current anti-migraine drugs. Headache 1990;30:5-11
6. Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 1960;10:1076-8
7. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995;45:219-23
8. Anonymous. Physicians' Desk Reference. 48th edn. Montvale NJ: Medical Economics Data Production Company 1994:792
9. Silberstein SD, Young WB for the Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Neurology 1995;45:577-84
10. Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatr 1990;51:222-5
11. Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatr 1990;51-126
12. Halman M, Goldbloom DS. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatr 1990;28:518-21
13. Durson SM, Mathew VM, Reveley MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 1993;342:442-3
14. Brannan SK, Talley BT, Bowden CL. Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol 1994;14:144-5
15. Klee B, Kronig MH. Case report of probably sertraline-induced akathisia. Am J Psychiatr 1993;150:986-7
16. Bhatara VS, Bandettini FC. Possible interaction between sertraline and tranylcypromine. Clin Pharm 1993;12:222-5
17. Lenzi A, Raffaelli S, Marazziti D. Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage. Pharmacopsychiatry 1993;26:100-1
18. Lejoyeux M, Fineyre F, Ades J. The serotonin syndrome. Am J Psychiatr 1992;149:1410-1
19. Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993;53:84-8
20. Goldberg RJ, Huk M. Serotonin syndrome from trazodone and buspirone. Psychosomatics 1992;33:235-6
21. Rivers N, Horner B. Possible lethal interaction between Nardil and dextromethorphan. Can Med Assoc J 1970;103:85
22. Sovner R, Wolfe J. Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid. N Engl J Med 1988;319:1671
23. Browne B, Linter S. Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment. Br J Psychiatr 1987;151:210-2
24. Mitchell RS. Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Intern Med 1955;42:417-24
25. Smilkstein MJ, Smolinske SC, Rumack BH. A case of MAO inhibitor/MDMA interaction: agony after ecstasy. J Toxicol Clin Toxicol 1987;25:149-59
26. Kaskey CB. Possible interaction between MOAI and "ecstasy". Am J Psychiatr 1992;149:411-2
27. Sandyk R. L-Dopa induces "serotonin syndrome" in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol 1986;6:194-5
28. Spigset O, Mjorndal T, Lovheim O. Serotonin caused by a moclobemide-clomipramine interaction. Br Med J 1993;306-248
29. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993;342-1419
30. Glassman AH, Platman SR. Potentiation of a monoamine oxidase inhibitor by tryptophan. J Psychiatr Res 1969;7:83-8
31. Baloh RW, Dietz J, Spooner JW. Myoclonus and ocular oscillations induced by L-tryptophan. Ann Neurol 1982;11:95-7
32. Insel TR, Roy BF, Cohen RM, Murphy DL. Possible development of the serotonin syndrome in man. Am J Psychiatr 1982;139:954-5
33. Thomas JM, Rubin EH. Case report of a toxic reaction from a combination of tryptophan and phenelzine. Am J Psychiatr 1984;141:281-3
34. Pope HG, Jonas JM, Hudson JL, Kafka MP. Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan. Am J Psychiatr 1985;142:491-2
35. Levy AB, Bucher P, Votolato N. Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine-tryptophan combination treatment. Can J Psychiatr 1985;30:434-6
36. Sternbach H. The serotonin syndrome. Am J Psychiatr 1991;148:705-13
37. Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine (letter). N Engl J Med 1994;331:1021-2